Fed. Circ. Affirms Valeant Win In Antidepressant IP Battle
In a per curiam order, a three-judge panel affirmed a 2011 decision holding that Watson, now Actavis Inc., failed to prove Valeant's four patents covering the time-release antidepressant were invalid due to reasons of anticipation and obviousness.
Watson sought to market a generic equivalent of Valeant's version of the popular...
Already a subscriber? Click here to login